H.C. Wainwright assumed coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $9 price target Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company’s leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics Updates Annual Meeting Time
- Unicycive Therapeutics announces time change for FY25 annual meeting
- Buy Rating for Unicycive Therapeutics Driven by Strategic Positioning and Upcoming Regulatory Milestones
- Unicycive Therapeutics reports Q1 EPS (5c), consensus (6c)
- Unicycive Therapeutics initiated with a Buy at Guggenheim